| breast cancer - HR positive | ||
| la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | |
| abemaciclib based treatment | ||
| abemaciclib plus aromatase inhibitor | MONARCH 3 | |
| abemaciclib plus endocrine therapy | MonarchE | |
| abemaciclib plus fulvestrant | MONARCH 2 | |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-